Genentech Shows Off Positive Results From Phase III HEMLIBRA, TECENTRIQ Studies Post author:Sam Post published:November 19, 2017 Post category:BioPharma Data will be submitted to health authorities globally, including the FDA and EMA. Source: BioSpace You Might Also Like SentreHEART Announces Positive Reimbursement Renewal Decision In Germany February 9, 2017 UK's Dechra Spends $422.1M on Two Dutch Animal Pharmas January 24, 2018 San Diego's Mirati Therapeutics Abandons Lead Drug, Shifts Focus November 14, 2017
